Gapping up
In reaction to strong earnings/guidance: NKE +8.5%, JBL +7.4%, AEHR +6.2%, (thinly traded), CTAS +1%
M&A news: AEG +3.9% ( to acquire Mercer HR Services' US defined contribution administration book of business ), RAI +2.3% (Bloomberg reporting Japan Tobacco is in talks to acquire ~$5 bln of RAI's assets)
Select Semi related names showing strength: ARMH +2.9%, ASML +2.8%, STM +2.6%, MU +1.7%
Other news: BLPH +76.1% (positive data from an interim analysis of its Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension; receives SPA for its phase 3 PAH program), VSTM +11.9% (reports a study published in the journal Cell, which highlights the potential of FAK inhibition to enable the body's immune system to fight cancer),MRVL +5.8% (announces significant restructuring of mobile platform business ), CTCM +5.8% (divests 75% interest in operating business for $200 mln; plans to return cash to shareholders), ACI +5% (cont strength), BTU +4.3% (cont strength), WMIH +4.1% (received approval to list on Nasdaq effective September 28), SUNE +3.9% (rebounding after recent sell off), EXEL+3.9% (confirms European CHMP positive opinion for Cobimetinib in combination with Vemurafenib for the treatment of advanced melanoma), ADRO +3.7% (to acquire BioNovion for EUR 29 mln), HZNP +3.2% (confirms it received a Positive CHMP Opinion for RAVICTI Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Age), UA+2.6% (on NKE results), OPK +2.6% (following CEO appearance on Mad Money), FCX +2.6% (cont strength from yesterday), SPWH +2.5% (prices its secondary offering of 6.25 mln shares of common stock at $12.25/share on behalf of selling stockholders), GPRO +2.2% (trading higher with futures pre-mkt), CNHI +2.1% (rebounding after yesterday's weakness), NVS +2.1% (receives CHMP recommendation for Entresto for EU approval), NVO +2.1% (reports second phase 3a trial with semaglutide in people with type 2 diabetes achieved its objective), SNY +2% (trading higher with peers), NFLX +1.9% (trading higher with futures pre-mkt), BIIB +1.9% (Biogen and Sobi confirm they received a positive recommendation from the CHMP for the marketing authorization of ELOCTA), GSK +1.4% (trading higher with peers), CELG +1.4% (receives positive CHMP opinion as new treatment for elderly patients with acute myeloid leukaemia), GILD +1.4% (European CHMP Adopts Positive Opinion for Gilead's Single Tablet Regimen Genvoya for the Treatment of HIV), AZN +1.2% (trading higher with peers), AAPL +1.2% (iPhone 6 released today), AMGN +1% (confirms the CHMP adopted positive opinions recommending marketing authorization for BLINCYTO and Kyprolis in combination with lenalidomide and dexamethasone)
Analyst comments: ARWR +6.1% (target raised to $20 from $12 at Piper Jaffray), CYBR +3.9% (upgraded to Buy from Neutral at Nomura), ARMH +3.4% (initiated with a Buy at Stifel), ERIC +2.3% (upgraded to Buy at Liberum), URI +2.1% (initiated with an Overweight at Barclays; upgraded to Neutral from Underperform at BofA/Merrill), ALV +1.8% (upgraded to Sector Perform at RBC Capital Mkts), INTC +1.5% (upgraded to Mkt Perform from Mkt Underperform at JMP Securities), NVRO +1.4% (initiated with an Outperform at BMO Capital), KO +1.1% (reinstated with a Buy at Deutsche Bank
)
In reaction to strong earnings/guidance: NKE +8.5%, JBL +7.4%, AEHR +6.2%, (thinly traded), CTAS +1%
M&A news: AEG +3.9% ( to acquire Mercer HR Services' US defined contribution administration book of business ), RAI +2.3% (Bloomberg reporting Japan Tobacco is in talks to acquire ~$5 bln of RAI's assets)
Select Semi related names showing strength: ARMH +2.9%, ASML +2.8%, STM +2.6%, MU +1.7%
Other news: BLPH +76.1% (positive data from an interim analysis of its Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension; receives SPA for its phase 3 PAH program), VSTM +11.9% (reports a study published in the journal Cell, which highlights the potential of FAK inhibition to enable the body's immune system to fight cancer),MRVL +5.8% (announces significant restructuring of mobile platform business ), CTCM +5.8% (divests 75% interest in operating business for $200 mln; plans to return cash to shareholders), ACI +5% (cont strength), BTU +4.3% (cont strength), WMIH +4.1% (received approval to list on Nasdaq effective September 28), SUNE +3.9% (rebounding after recent sell off), EXEL+3.9% (confirms European CHMP positive opinion for Cobimetinib in combination with Vemurafenib for the treatment of advanced melanoma), ADRO +3.7% (to acquire BioNovion for EUR 29 mln), HZNP +3.2% (confirms it received a Positive CHMP Opinion for RAVICTI Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Age), UA+2.6% (on NKE results), OPK +2.6% (following CEO appearance on Mad Money), FCX +2.6% (cont strength from yesterday), SPWH +2.5% (prices its secondary offering of 6.25 mln shares of common stock at $12.25/share on behalf of selling stockholders), GPRO +2.2% (trading higher with futures pre-mkt), CNHI +2.1% (rebounding after yesterday's weakness), NVS +2.1% (receives CHMP recommendation for Entresto for EU approval), NVO +2.1% (reports second phase 3a trial with semaglutide in people with type 2 diabetes achieved its objective), SNY +2% (trading higher with peers), NFLX +1.9% (trading higher with futures pre-mkt), BIIB +1.9% (Biogen and Sobi confirm they received a positive recommendation from the CHMP for the marketing authorization of ELOCTA), GSK +1.4% (trading higher with peers), CELG +1.4% (receives positive CHMP opinion as new treatment for elderly patients with acute myeloid leukaemia), GILD +1.4% (European CHMP Adopts Positive Opinion for Gilead's Single Tablet Regimen Genvoya for the Treatment of HIV), AZN +1.2% (trading higher with peers), AAPL +1.2% (iPhone 6 released today), AMGN +1% (confirms the CHMP adopted positive opinions recommending marketing authorization for BLINCYTO and Kyprolis in combination with lenalidomide and dexamethasone)
Analyst comments: ARWR +6.1% (target raised to $20 from $12 at Piper Jaffray), CYBR +3.9% (upgraded to Buy from Neutral at Nomura), ARMH +3.4% (initiated with a Buy at Stifel), ERIC +2.3% (upgraded to Buy at Liberum), URI +2.1% (initiated with an Overweight at Barclays; upgraded to Neutral from Underperform at BofA/Merrill), ALV +1.8% (upgraded to Sector Perform at RBC Capital Mkts), INTC +1.5% (upgraded to Mkt Perform from Mkt Underperform at JMP Securities), NVRO +1.4% (initiated with an Outperform at BMO Capital), KO +1.1% (reinstated with a Buy at Deutsche Bank
)